•Incidence: 1 % •Associated features –Plasmablastic morphology –Other extramedullary locations –Plasma cell leukemia –Increased lactate dehydrogenase •MRI: diffuse leptomeningeal enhancement (with or without masses) •Median survival: 3 months Modified with…
Alkylating agent therapy DNA-topoisomerase II inhibitor therapy (epipodophyllotoxins and anthracyclines) Intense therapy High doses of chemotherapy for prolonged periods as in therapy for Hodgkin’s disease and non-Hodgkin’s lymphoma Direct correlation…
Acute myeloid leukemia with recurrent genetic abnormalities AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (AML1-ETO) [M2] AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 [M4Eo] APL with t(15;17)(q22;q12); PML-RARA [M3] AML with t(9;11)(p22;q23); MLLT3-MLL AML…
Complete medical history, including •Past medical history, especially heart, lung, liver or renal disease, and diabetes mellitus (comorbidity score) •Family history •Occupational history Complete physical examination, with special attention to…
Fig. 15.1 US acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) incidence rates (age-adjusted, 2000 US standard) by race and sex, diagnosed among residents of nine cancer registry areas…
CrossRef 3. Piller G. The history of leukemia: a personal perspective. Blood Cells. 1993;19:521.PubMed 4. Velpeau A. Sur la resorption du puseat sur l’altération du sang dans les maladies clinique…
4. Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer. 1949;2:943–5.PubMed
Acute haemorrhage Malignant disease (e.g. carcinoma, Hodgkin and non-Hodgkin lymphoma) Chronic inflammatory disorders (e.g. rheumatoid arthritis, ulcerative colitis) Acute inflammation Post-operation Splenectomy and hyposplenism Marrow recovery from drug suppression, or…
Time of observation Number of patients Incidence crude Incidence (WSP)a SEER [28] 1998–2000 – – 1.8b 2003–2007 4,653 – 1.7b France [35] 1985–2006 906 – 0.8 Swedish Cancer…
Working groups: NCIWG/IWCLL [2] Parameter Diagnosis Lymphocytes (× 109/L) >5; ≥1 B-cell marker (CD19, CD20, CD23) + CD5 Atypical cells (%) (e.g. prolymphocytes) <55 Duration of lymphocytosis At least…
